PMID- 40961426
OWN - NLM
STAT- MEDLINE
DCOM- 20250917
LR  - 20250917
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 393
IP  - 11
DP  - 2025 Sep 18
TI  - Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer.
PG  - 1051-1064
LID - 10.1056/NEJMoa2504650 [doi]
AB  - BACKGROUND: Aspirin reduces the incidence of colorectal adenoma and colorectal 
      cancer among high-risk persons. Observational studies suggest that aspirin may 
      also improve disease-free survival after diagnosis, particularly among patients 
      with tumors harboring somatic PIK3CA mutations. However, data from randomized 
      trials are lacking. METHODS: We conducted a double-blind, randomized, 
      placebo-controlled trial involving patients with stage I, II, or III rectal 
      cancer or stage II or III colon cancer with somatic alterations in PI3K pathway 
      genes. The patients were assigned in a 1:1 ratio to receive 160 mg of aspirin or 
      matched placebo once daily for 3 years. Patients with prespecified PIK3CA hotspot 
      mutations in exon 9 or 20 (group A alterations) and those with other moderate- or 
      high-impact somatic variants in PIK3CA, PIK3R1, or PTEN (group B alterations) 
      were eligible for randomization. The primary end point was colorectal cancer 
      recurrence, assessed in a time-to-event analysis, in patients with group A 
      alterations. Secondary end points included colorectal cancer recurrence in 
      patients with group B alterations, disease-free survival, and safety. RESULTS: 
      Alterations in PI3K pathway genes were detected in 1103 of 2980 patients (37.0%) 
      with complete genomic data. Of 515 patients with group A alterations and 588 
      patients with group B alterations, 314 and 312, respectively, were assigned to 
      receive aspirin or placebo. The estimated 3-year cumulative incidence of 
      recurrence was 7.7% with aspirin and 14.1% with placebo (hazard ratio, 0.49; 95% 
      confidence interval [CI], 0.24 to 0.98; P = 0.04) among patients with group A 
      alterations and 7.7% and 16.8%, respectively (hazard ratio, 0.42; 95% CI, 0.21 to 
      0.83), among those with group B alterations. The estimated 3-year disease-free 
      survival was 88.5% with aspirin and 81.4% with placebo (hazard ratio, 0.61; 95% 
      CI, 0.34 to 1.08) among patients with group A alterations and 89.1% and 78.7%, 
      respectively (hazard ratio, 0.51; 95% CI, 0.29 to 0.88), among those with group B 
      alterations. Severe adverse events occurred in 16.8% of aspirin recipients and 
      11.6% of placebo recipients. CONCLUSIONS: Aspirin led to a significantly lower 
      incidence of colorectal cancer recurrence than placebo among patients with PIK3CA 
      hotspot mutations in exon 9 or 20 and appeared to have a similar benefit among 
      those with other somatic alterations in PI3K pathway genes. (Funded by the 
      Swedish Research Council and others; ALASCCA ClinicalTrials.gov number, 
      NCT02647099; EudraCT number, 2015-004240-19.).
CI  - Copyright © 2025 Massachusetts Medical Society.
FAU - Martling, Anna
AU  - Martling A
AUID- ORCID: 0000-0001-5998-4735
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm.
AD  - Theme Cancer, Department of Pelvic Cancer, Karolinska University Hospital, 
      Stockholm.
FAU - Hed Myrberg, Ida
AU  - Hed Myrberg I
AD  - Clinical Epidemiology Division, Department of Medicine Solna, Karolinska 
      Institutet, Stockholm.
FAU - Nilbert, Mef
AU  - Nilbert M
AD  - Institute of Clinical Sciences, Lund University and Skane University Hospital 
      Cancer Center, Lund, Sweden.
FAU - Grönberg, Henrik
AU  - Grönberg H
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm.
FAU - Granath, Fredrik
AU  - Granath F
AD  - Clinical Epidemiology Division, Department of Medicine Solna, Karolinska 
      Institutet, Stockholm.
FAU - Eklund, Martin
AU  - Eklund M
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm.
FAU - Öresland, Tom
AU  - Öresland T
AD  - Department of Gastrointestinal Surgery, Akershus University Hospital, Oslo.
AD  - Clinic for Surgical Sciences, University of Oslo, Oslo.
FAU - Iversen, Lene H
AU  - Iversen LH
AD  - Department of Surgery, Aarhus University Hospital, Department of Clinical 
      Medicine, Aarhus University, Aarhus, Denmark.
FAU - Haapamäki, Carola
AU  - Haapamäki C
AD  - Department of Gastroenterologic Surgery, Helsinki University Hospital and 
      University of Helsinki, Helsinki.
FAU - Janson, Martin
AU  - Janson M
AD  - Department of Clinical Science and Education, Stockholm South General Hospital, 
      Stockholm.
FAU - Westberg, Karin
AU  - Westberg K
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm.
AD  - Danderyds Hospital, Department of Surgery, Stockholm.
FAU - Segelman, Josefin
AU  - Segelman J
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm.
AD  - Ersta Hospital, Department of Surgery, Stockholm.
FAU - Ersson, Urban
AU  - Ersson U
AD  - Skaraborg Hospital, Skövde, Sweden.
FAU - Prytz, Mattias
AU  - Prytz M
AD  - Department of Surgery, Region Västra Götaland, NU Hospital group, Trollhättan, 
      Sweden.
AD  - Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, 
      University of Gothenburg, Gothenburg, Sweden.
FAU - Angenete, Eva
AU  - Angenete E
AUID- ORCID: 0000-0001-9966-4904
AD  - Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, 
      University of Gothenburg, Gothenburg, Sweden.
AD  - Department of Surgery, Sahlgrenska University Hospital-Östra, Region Västra 
      Götaland, Gothenburg, Sweden.
FAU - Bergström, Rebecka
AU  - Bergström R
AUID- ORCID: 0000-0001-7609-0733
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm.
FAU - Mayrhofer, Markus
AU  - Mayrhofer M
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm.
AD  - National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, 
      Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
FAU - Glimelius, Bengt
AU  - Glimelius B
AD  - Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, 
      Sweden.
FAU - Lindberg, Johan
AU  - Lindberg J
AD  - Department of Medical Epidemiology and Biostatistics, Science for Life 
      Laboratory, Karolinska Institutet, Stockholm.
CN  - ALASCCA Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT02647099
SI  - EudraCT/2015-004240-19
GR  - 2014-38551-117568-77/Vetenskapsrådet/
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - R16CO5Y76E (Aspirin)
RN  - EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.137 (PIK3CA protein, human)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.1.- (PIK3R1 protein, human)
RN  - EC 2.7.1.137 (Class Ia Phosphatidylinositol 3-Kinase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Aspirin/administration & dosage/adverse effects
MH  - *Class I Phosphatidylinositol 3-Kinases/genetics
MH  - Disease-Free Survival
MH  - Double-Blind Method
MH  - Mutation
MH  - Neoplasm Recurrence, Local/epidemiology/genetics/prevention & control
MH  - *Phosphatidylinositol 3-Kinases/genetics
MH  - PTEN Phosphohydrolase/genetics
MH  - *Colonic Neoplasms/drug therapy/genetics/mortality/pathology
MH  - *Rectal Neoplasms/drug therapy/genetics/mortality/pathology
MH  - Neoplasm Staging
MH  - Dose-Response Relationship, Drug
MH  - Incidence
MH  - *Biomarkers, Tumor/genetics
MH  - Class Ia Phosphatidylinositol 3-Kinase/genetics
MH  - Aged, 80 and over
FIR - Martling, Anna
IR  - Martling A
FIR - Glimelius, Bengt
IR  - Glimelius B
FIR - Grönberg, Henrik
IR  - Grönberg H
FIR - Nilbert, Mef
IR  - Nilbert M
FIR - Lindberg, Johan
IR  - Lindberg J
FIR - Bergström, Rebecka
IR  - Bergström R
FIR - Mayrhofer, Markus
IR  - Mayrhofer M
FIR - Chellappa, Venkatesh
IR  - Chellappa V
FIR - Myrberg, Ida Hed
IR  - Myrberg IH
FIR - Eloranta, Sandra
IR  - Eloranta S
FIR - Dominicus, Annika
IR  - Dominicus A
FIR - Granath, Fredrik
IR  - Granath F
FIR - Ahlberg, Madelene
IR  - Ahlberg M
FIR - Süllow Barin, Sabine
IR  - Süllow Barin S
FIR - Angenete, Eva
IR  - Angenete E
FIR - Malik, Zunash
IR  - Malik Z
FIR - Loftås, Per
IR  - Loftås P
FIR - Olsson, Malin
IR  - Olsson M
FIR - Westberg, Karin
IR  - Westberg K
FIR - Karlsson, Josefin
IR  - Karlsson J
FIR - Segelman, Josefin
IR  - Segelman J
FIR - Jaksic, Dubravka
IR  - Jaksic D
FIR - Lédel, Frida
IR  - Lédel F
FIR - Bernhoff, Richard
IR  - Bernhoff R
FIR - Janson, Martin
IR  - Janson M
FIR - Jansson Grönwald, Bastan
IR  - Jansson Grönwald B
FIR - Ersson, Urban
IR  - Ersson U
FIR - Wennström, Berith
IR  - Wennström B
FIR - Prytz, Mattias
IR  - Prytz M
FIR - Samuelsson, Malin
IR  - Samuelsson M
FIR - Sadeghi, Marcel
IR  - Sadeghi M
FIR - Leppänen, Anna
IR  - Leppänen A
FIR - Syk, Ingvar
IR  - Syk I
FIR - Nilsson, Caroline
IR  - Nilsson C
FIR - Flygare, Petra
IR  - Flygare P
FIR - Näslund, Christine
IR  - Näslund C
FIR - Haapamäki, Markku
IR  - Haapamäki M
FIR - Karhu, Agneta
IR  - Karhu A
FIR - Odensten, Christoffer
IR  - Odensten C
FIR - Näsvall, Pia
IR  - Näsvall P
FIR - Haapaniemi, Staffan
IR  - Haapaniemi S
FIR - Benckert, Anna
IR  - Benckert A
FIR - Laurell, Helena
IR  - Laurell H
FIR - Nordén, Morgan
IR  - Nordén M
FIR - Olofsson, Åsa
IR  - Olofsson Å
FIR - Birgisson, Helgi
IR  - Birgisson H
FIR - Lidén, Annika
IR  - Lidén A
FIR - Smed, Kenneth
IR  - Smed K
FIR - Engdahl, Malin
IR  - Engdahl M
FIR - Zar, Niklas
IR  - Zar N
FIR - Karlsson, Therése
IR  - Karlsson T
FIR - Söderholm, Mattias
IR  - Söderholm M
FIR - Olsson, Monica
IR  - Olsson M
FIR - Matthiessen, Peter
IR  - Matthiessen P
FIR - Hansson, Lena
IR  - Hansson L
FIR - Persson, Kamilla
IR  - Persson K
FIR - Nyqvist, Karin
IR  - Nyqvist K
FIR - Øresland, Tom
IR  - Øresland T
FIR - Aarstad Merok, Marianne
IR  - Aarstad Merok M
FIR - Helgeland, Merete
IR  - Helgeland M
FIR - Lossius, William
IR  - Lossius W
FIR - Wasmuth, Hans
IR  - Wasmuth H
FIR - Veen, Torhild
IR  - Veen T
FIR - Khajavi-Larsen, Ramesh
IR  - Khajavi-Larsen R
FIR - Dehli, Trond
IR  - Dehli T
FIR - Woll, Kristin
IR  - Woll K
FIR - Iversen, Lene H
IR  - Iversen LH
FIR - Haupt, Kirsten
IR  - Haupt K
FIR - Haas, Susanne
IR  - Haas S
FIR - Emmertsen, Katrine J
IR  - Emmertsen KJ
FIR - Boesen Bräuner, Annette
IR  - Boesen Bräuner A
FIR - Bundgård, Lea
IR  - Bundgård L
FIR - Haapamäki, Carola
IR  - Haapamäki C
FIR - Keränen, Ilona
IR  - Keränen I
FIR - Koskensalo, Selja
IR  - Koskensalo S
FIR - Lehtonen, Taru
IR  - Lehtonen T
FIR - Ekbom, Anders
IR  - Ekbom A
FIR - Hultcrantz, Rolf
IR  - Hultcrantz R
FIR - Permert, Johan
IR  - Permert J
EDAT- 2025/09/17 18:31
MHDA- 2025/09/17 18:32
CRDT- 2025/09/17 16:13
PHST- 2025/09/17 18:32 [medline]
PHST- 2025/09/17 18:31 [pubmed]
PHST- 2025/09/17 16:13 [entrez]
AID - 10.1056/NEJMoa2504650 [doi]
PST - ppublish
SO  - N Engl J Med. 2025 Sep 18;393(11):1051-1064. doi: 10.1056/NEJMoa2504650.
